Director Michael Schmertzler purchased $1,999,995 (66,225 shares) of PTC Therapeutics, inc. PTCT stock through his fund Sections Six Partners, LP on 1/25/2019. The stock was down ~40% off of its Oct 1 peak at purchase.
If you found this post helpful, consider visiting a few of our sponsors who have offers that may be relevant to you.
